Marinus Pharmaceuticals Inc.

2 trials Commercial sponsor

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

0 Recruiting

3 Completed trials

14 Countries active

1 Unique IMPs

100% Results reported

Phase III

Oversight events:

1 urgent safety measure across 1 trial

View oversight register →

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Status epilepticus 1

Top IMPs

All trials

2 total

A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to s… Ended

2022-502540-12-00 Phase III 14 countries GANAXOLONE
A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Ep… Ended

2022-503067-15-00 Phase III 5 countries GANAXOLONE

Showing 1–2 of 2 trials

← All sponsors A–Z